Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by langostaon Nov 28, 2017 8:03pm
71 Views
Post# 27050468

RE:RE:Ph2 looks very good, just waiting on word of the remaining 5

RE:RE:Ph2 looks very good, just waiting on word of the remaining 5
jojomarch wrote: Xmas/ New Year's "wish" list:
1. Finish Ph1b 5 remaining patient - 30 day look see A OKAY.   High dose slows UUTUC confirmed.   
2. Ph2 approval follows quickly in New Year
3. Partnership announced with cost sharing and support for Ph2.
3.1 Partnership includes licensing agreement for several global market regions.  Large cash payment upfront. 
4. Super compound results from TLT and PMR are stunning, more insights discovered.
5. Ph2 protocol includes means to better address UUTUC including pre-treat with the 2000 and re-treatments of compound with activation allowed.
6. Ph2 includes exploratory work on vaccine and/or immune system enhancements 
7. GBM Ph1 pursued with 2000 pre-treat, PDC with Xray activation (with re-treats) and vaccine development. Partner with big pharma cost sharing with licensing option paid upfront.  

All licensing/partnerships includes marketing, training, market development, royalties. branding etc.

2020 Big pharma GBM partner bids full take out.  $30B offer is quickly out bid to $40B.  Bidding erupts... 

ME TOO
THANK YOU  VESTOR




My Xmas/New Year's wish list:

All I ask is a chance to prove that money can't make me happy. 

Bullboard Posts